Nick Andrews

Summary

Affiliation: Health Protection Agency
Country: UK

Publications

  1. ncbi request reprint Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era
    Caroline Trotter
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 21:1094-8. 2003
  2. doi request reprint Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
    Nick J Andrews
    Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
    Vaccine 30:6802-8. 2012
  3. pmc Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales
    Nick Andrews
    Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e28435. 2011
  4. doi request reprint Epidemiological designs for vaccine safety assessment: methods and pitfalls
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London, NW9 5EQ, UK
    Biologicals 40:389-92. 2012
  5. doi request reprint A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Vaccine 30:3042-6. 2012
  6. doi request reprint Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Nick J Andrews
    Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
    Vaccine 29:7913-9. 2011
  7. doi request reprint Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Vaccine 29:7878-82. 2011
  8. ncbi request reprint Post-licensure safety of the meningococcal group C conjugate vaccine
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, London, UK
    Hum Vaccin 3:59-63. 2007
  9. pmc Towards elimination: measles susceptibility in Australia and 17 European countries
    Nick Andrews
    Centre for Infections, Health Protection Agency, London, England
    Bull World Health Organ 86:197-204. 2008
  10. doi request reprint Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 28:7215-20. 2010

Detail Information

Publications92

  1. ncbi request reprint Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era
    Caroline Trotter
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 21:1094-8. 2003
    ..This study provides baseline antibody levels which will facilitate the evaluation of the meningococcal serogroup C conjugate vaccination programme...
  2. doi request reprint Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
    Nick J Andrews
    Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
    Vaccine 30:6802-8. 2012
    ..Based on the VE estimates PPV23 was still considered a cost-effective intervention for the low risk elderly...
  3. pmc Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales
    Nick Andrews
    Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e28435. 2011
    ..We estimated the effectiveness of PCV-7 against IPD...
  4. doi request reprint Epidemiological designs for vaccine safety assessment: methods and pitfalls
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London, NW9 5EQ, UK
    Biologicals 40:389-92. 2012
    ..The example of MMR and autism, where all three designs have been used, is presented to help consider these issues...
  5. doi request reprint A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Vaccine 30:3042-6. 2012
    ..The study therefore shows the potential for vaccine safety collaborations across Europe to detect true associations through use of common protocols and sharing of results or data...
  6. doi request reprint Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Nick J Andrews
    Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
    Vaccine 29:7913-9. 2011
    ..Reduction in the interval between doses for earlier protection would be at the cost of reduced immunogenicity. The effect of seasonal vaccine on immunogenicity merits further investigation...
  7. doi request reprint Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Vaccine 29:7878-82. 2011
    ..05 [95% confidence interval (CI) 0.37 to 2.24]). We found no evidence of an increased risk of GBS in the 6 weeks following pandemic influenza vaccination...
  8. ncbi request reprint Post-licensure safety of the meningococcal group C conjugate vaccine
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, London, UK
    Hum Vaccin 3:59-63. 2007
    ..15 (0.80-1.67). There was evidence of an increased risk of convulsions and idiopathic thrombocytopenic purpura following MMR vaccination as previously documented...
  9. pmc Towards elimination: measles susceptibility in Australia and 17 European countries
    Nick Andrews
    Centre for Infections, Health Protection Agency, London, England
    Bull World Health Organ 86:197-204. 2008
    ..To evaluate age-specific measles susceptibility in Australia and 17 European countries...
  10. doi request reprint Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 28:7215-20. 2010
    ..Although there were no other significant differences between vaccines the relative incidence was significantly above one on the day of vaccination for convulsions following DTwP/Hib and for apnoea/collapse following DTaP(5)/Hib/IPV...
  11. pmc Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 17:154-9. 2010
    ....
  12. pmc Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 16:194-9. 2009
    ..This study demonstrates that NeisVac-C and Menjugate generate good immunogenicity after the first dose at 2 months of age when coadministered with PCV7 and Pediacel and merit further investigation in single-dose priming strategies...
  13. doi request reprint Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom
    David Goldblatt
    Immunobiology Unit, UCL Institute of Child Health, London, United Kingdom
    Pediatr Infect Dis J 29:401-5. 2010
    ..This study was conducted to establish the immunogenicity of licensed PCV (Prevenar) at a reduced, 2 priming dose schedule (2+1) and to evaluate functional responses in the context of vaccine effectiveness...
  14. pmc Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 18:367-72. 2011
    ..The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age...
  15. ncbi request reprint Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, UK
    Hum Vaccin 2:237-42. 2006
    ..This single blind study was conducted to address safety concerns regarding coadministration of diphtheria/ tetanus (DT,Td) boosters and meningococcal C conjugate (MCC) vaccines containing diphtheria or tetanus conjugate proteins...
  16. pmc Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011
    Katja Hoschler
    Respiratory Virus Unit, Virus Reference Department, Microbiology Services Colindale, Health Protection Agency, 61 Colindale Ave, London, NW9 5HT, UK
    Emerg Infect Dis 18:1894-7. 2012
    ..Population-based seroepidemiology confirms that the third wave of influenza A(H1N1)pdm09 virus circulation was associated with a shift in age groups affected, with the highest rate of infection in young adults...
  17. pmc Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study
    Stefan Flasche
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS Med 8:e1001017. 2011
    ....
  18. doi request reprint Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom
    Helen Findlow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Pediatr Infect Dis J 31:616-22. 2012
    ..Recent data have demonstrated that 2 of the 3 MCC vaccines showed potential for use as a single priming dose in infancy...
  19. pmc 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?
    Yoon Hong Choi
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e26190. 2011
    ..However, recent surveillance data show a more rapid replacement of PCV7 IPD cases by non-PCV7 IPD cases than was seen in the US...
  20. pmc Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation
    Marc Baguelin
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e17074. 2011
    ..The method provides a more accurate and continuous measure of incidence than achieved by comparing prevalence in samples grouped by time period...
  21. pmc Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in inf
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 14:1328-33. 2007
    ..15 microg/ml in about 90% of individuals. A booster dose of Hib vaccine given after the first year of life should provide long-lasting protection...
  22. ncbi request reprint Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
    Cressida Auckland
    Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
    J Infect Dis 194:1745-52. 2006
    ..The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data...
  23. pmc Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets
    Anthony Nardone
    Centre for Infections, Health Protection Agency, London, England
    Bull World Health Organ 86:118-25. 2008
    ..To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets...
  24. doi request reprint The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    J Infect 65:17-24. 2012
    ..Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects...
  25. doi request reprint Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, London, UK
    Lancet 375:1100-8. 2010
    ....
  26. pmc Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Clin Vaccine Immunol 17:840-7. 2010
    ..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016...
  27. ncbi request reprint Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London, NW9 5EQ, UK
    J Infect 55:394-9. 2007
    ....
  28. doi request reprint Effectiveness of trivalent and pandemic influenza vaccines in England and Wales 2008-2010: results from a cohort study in general practice
    Pia Hardelid
    Statistics Unit, Health Protection Agency Centre for Infections, London, UK
    Vaccine 30:1371-8. 2012
    ..The cohort study design could be used each season to estimate VE; however, residual confounding by indication could still present issues, despite adjustment for propensity to consult...
  29. doi request reprint No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 27:1422-5. 2009
    ....
  30. pmc Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave, Colindale, London, United Kingdom
    Clin Diagn Lab Immunol 11:1100-4. 2004
    ..The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower...
  31. doi request reprint Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay
    Norman K Fry
    Public Health England Respiratory and Vaccine Preventable Bacteria Reference Unit, Colindale, London, UK
    J Med Microbiol 62:1281-9. 2013
    ..These data will greatly assist the interpretation of single high diagnostic anti-PT IgG titres by allowing an estimate of the positive predictive value, when the number of days post-immunization and prevalence are known or assumed...
  32. pmc Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 7:e39150. 2012
    ..We investigated the effect of serotype on clinical presentation, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13)...
  33. doi request reprint No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England
    Richard Pebody
    Health Protection Agency Centre for Infections, 61 Colindale Avenue, UK
    Vaccine 29:2613-8. 2011
    ..Vaccine effectiveness did not differ significantly by age-group or hospitalisation status. There was no evidence prior vaccination with TIV significantly altered subsequent risk of pandemic influenza H1N1 2009 infection...
  34. doi request reprint Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Am J Epidemiol 169:382-8. 2009
    ....
  35. pmc Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England
    Nick Andrews
    Statistics Unit, Hepatitis, and Blood Safety Department, Health Protection Agency Centre for Infections, London, England
    J Infect Dis 203:32-9. 2011
    ..The use of a squalene-containing (AS03) pandemic vaccine for high-risk groups in England allowed vaccine effectiveness (VE) of such novel oil-in-water adjuvanted vaccine to be evaluated...
  36. pmc Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006
    Chee Fu Yung
    Health Protection Agency Centre for Infections, London, UK
    Emerg Infect Dis 17:661-7; quiz 766. 2011
    ..14-0.56) when patient had received 1 dose of measles, mumps, and rubella vaccine. The protective effect of vaccination on disease severity is critical in assessing the total effects of current and future mumps control strategies...
  37. doi request reprint Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains
    Katja Hoschler
    Health Protection Agency, Specialist and Reference Microbiology Division, ERNVL, Influenza Unit, Centre for Infections, 61 Colindale Avenue, London, UK
    Influenza Other Respir Viruses 1:199-206. 2007
    ..Their continuing circulation represents serious pandemic threat, spurring human vaccine development efforts. Initial clinical trials tested vaccines prepared from clade 1 strains circulating in 2004...
  38. doi request reprint Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort
    Angie Lackenby
    Microbiology Services Colindale, Public Health England, London, UK
    J Antimicrob Chemother 68:2324-31. 2013
    ..To perform antiviral susceptibility monitoring of treated individuals in the community during the 2009 influenza A(H1N1) pandemic in England...
  39. ncbi request reprint Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association
    Nick Andrews
    Statistics Unit, Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom
    Pediatrics 114:584-91. 2004
    ....
  40. pmc Accelerating control of pertussis in England and Wales
    Helen Campbell
    Health Protection Agency, London, UK
    Emerg Infect Dis 18:38-47. 2012
    ..e., <3 months of age), teenagers, and adults. Future vaccine program changes may be beneficial, but additional detail is required to inform such decisions...
  41. doi request reprint Development of a focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing antibodies
    Sunil R Vaidya
    Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    J Virol Methods 163:153-6. 2010
    ..150 microL), and the possibility of automation using 96-well plates. FRNT appears to be a good substitute for PRNT for characterising the immune response to mumps and for vaccine efficacy studies...
  42. doi request reprint Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England
    Nigel Field
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom 1 Research Department of Infection and Population Health, University College London, Mortimer Market Centre, off Capper Street, London WC1E 6JB, United Kingdom Electronic address
    Vaccine 32:1213-7. 2014
    ..To inform this approach, we estimated the proportion of adolescents with varicella antibodies by reported chickenpox history...
  43. pmc The social life of infants in the context of infectious disease transmission; social contacts and mixing patterns of the very young
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, England
    PLoS ONE 8:e76180. 2013
    ..The least contact was between adolescents and infants. Thus the impact of adolescent (pertussis) vaccination on infants would likely be limited, unless it reduces transmission to other age groups whose contact with infants is greater...
  44. doi request reprint Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, UK
    BMJ 346:f794. 2013
    ..To evaluate the risk of narcolepsy in children and adolescents in England targeted for vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine (Pandemrix) from October 2009...
  45. doi request reprint The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales
    Mark Jit
    Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 6BT, United Kingdom
    Vaccine 29:115-22. 2010
    ..Key sources of uncertainty are the cost of vaccine delivery and the quality of life detriment due to a clinically apparent episode of confirmed influenza. The cost of vaccine purchase itself is relatively low...
  46. pmc No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
    Brent Taylor
    General and Adolescent Paediatric Unit, Institute of Child Health, University College London, London, UK
    Arch Dis Child 92:887-9. 2007
    ..To investigate whether meningococcal C conjugate vaccine (MCCV) caused relapse in children with steroid-responsive nephrotic syndrome...
  47. pmc Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Nick Andrews
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
    Clin Diagn Lab Immunol 10:780-6. 2003
    ....
  48. pmc Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew R Gorringe
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Clin Vaccine Immunol 16:1113-20. 2009
    ..In conclusion, this N. lactamica OMV vaccine is safe and induces a weak but broad humoral immune response to N. meningitidis...
  49. ncbi request reprint Bell's palsy and parenteral inactivated influenza vaccine
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Hum Vaccin 2:110-2. 2006
    ..78-1.08). There was also no evidence of an increased risk in any age group or following pneumococcal vaccine. A significant increase was seen on the day of vaccination (day 0) probably due to opportunistic recording of cases...
  50. doi request reprint Effectiveness of seasonal influenza vaccine in preventing medically attended influenza infection in England and Wales during the 2010/2011 season: a primary care-based cohort study
    George Kafatos
    Statistics Unit, Public Health England, London, UK
    Influenza Other Respir Viruses 7:1175-80. 2013
    ..Estimates of seasonal influenza vaccine effectiveness (VE) are affected by factors such as the strain of the current circulating influenza virus and characteristics of the host...
  51. doi request reprint Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study
    Julia Stowe
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    Vaccine 29:9467-72. 2011
    ..These results neither provide evidence of an increased risk of convulsions following TIV over a 10-year surveillance period nor following a single dose of the ASO3 adjuvanted monovalent H1N1 vaccine in 2009/10...
  52. ncbi request reprint Rabies antibody levels in bat handlers in the United Kingdom: immune response before and after purified chick embryo cell rabies booster vaccination
    Jill Morris
    Immunisation Department, Centre for Infections, Health Protection Agency, London, UK
    Hum Vaccin 3:165-70. 2007
    ..We recommend that the first rabies booster vaccination is given one year after the primary course and subsequent boosters are given every three to five years thereafter...
  53. ncbi request reprint Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination
    Bernard J Cohen
    Centre for Infections, Health Protection Agency, London NW9 5EQ, UK
    Vaccine 26:59-66. 2007
    ..Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy...
  54. pmc Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006
    ..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease...
  55. ncbi request reprint Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children
    Jamie Findlow
    Vaccine Evaluation Department, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Vaccine 23:2623-7. 2005
    ..This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines...
  56. pmc Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals
    Paul Balmer
    Manchester Laboratory, Health Protection Agency North West, Manchester Medical Microbiology Partnership, Manchester M13 9WZ, United Kingdom
    Infect Immun 72:332-7. 2004
    ..We recommend that, following vaccination of asplenics, either the level of functional antibody should be determined, with a second dose of MCC vaccine offered to nonresponders, or two doses of MCC vaccine should be routinely offered...
  57. ncbi request reprint Immune response to pneumococcal conjugate vaccination in asplenic individuals
    Elaine Stanford
    Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK
    Hum Vaccin 5:85-91. 2009
    ..Although immunogenic, there is insufficient evidence here to recommend routine PCV7 immunization over PPV23 immunization in adult asplenic individuals...
  58. doi request reprint Cluster-sample surveys and lot quality assurance sampling to evaluate yellow fever immunisation coverage following a national campaign, Bolivia, 2007
    Lorenzo Pezzoli
    European Programme for Intervention Epidemiology Training, European Centre for Disease Control, Stockholm, Sweden
    Trop Med Int Health 14:355-61. 2009
    ..To estimate the yellow fever (YF) vaccine coverage for the endemic and non-endemic areas of Bolivia and to determine whether selected districts had acceptable levels of coverage (>70%)...
  59. pmc Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
    Clin Vaccine Immunol 14:1451-7. 2007
    ..These results have implications for the choice of MenB target strains for inclusion in future studies of MenB vaccines and highlight the requirement for standardization of target strains between laboratories...
  60. pmc Mortality Attributable to Influenza in England and Wales Prior to, during and after the 2009 Pandemic
    Helen K Green
    Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control, Public Health England, London, United Kingdom
    PLoS ONE 8:e79360. 2013
    ..This analysis forms part of the preparatory work to establish a routine mortality monitoring system ahead of introduction of the UK universal childhood seasonal influenza vaccination programme in 2013/14. ..
  61. pmc Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in England
    Chee Fu Yung
    Department of Clinical Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore, Singapore
    PLoS ONE 8:e56844. 2013
    ..Current immunogenicity licensing criteria for pandemic influenza vaccine may not correlate with clinical protection in individuals with chronic disease or immunocompromised...
  62. doi request reprint Regression models for censored serological data
    George Kafatos
    Department of Statistics, Modelling and Economics, Health Protection Agency, London, UK
    J Med Microbiol 62:93-100. 2013
    ..Censored regression produced the least biased estimates in comparison with the other methods examined. Moreover, the results suggest using interval-censored regression methods for assay data resulting from dilution series...
  63. doi request reprint Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study
    Dominik Zenner
    Health Protection Agency, Health Protection Services Colindale, London, UK
    Am J Respir Crit Care Med 185:779-84. 2012
    ..The aim of this study was to analyze the epidemiology of TB in pregnancy, and to establish whether pregnancy is an independent risk factor for TB...
  64. doi request reprint Has estimation of numbers of cases of pandemic influenza H1N1 in England in 2009 provided a useful measure of the occurrence of disease?
    Barry Evans
    Health Protection Agency, Centre for Infections, London, UK
    Influenza Other Respir Viruses 5:e504-12. 2011
    ..An approach was developed to estimate the number of cases of influenza-like illness (ILI) occurring because of infection with pandemic influenza virus...
  65. doi request reprint Clustered lot quality assurance sampling to assess immunisation coverage: increasing rapidity and maintaining precision
    Lorenzo Pezzoli
    Epidemiology Consultant, London, UK
    Trop Med Int Health 15:540-6. 2010
    ....
  66. pmc Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey
    Jonathan P Clewley
    Centre for Infections, Health Protection Agency, London NW9 5EQ
    BMJ 338:b1442. 2009
    ....
  67. ncbi request reprint Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, Colindale, London, UK
    Vaccine 23:3829-35. 2005
    ....
  68. ncbi request reprint Stability of total and rubella-specific IgG in oral fluid samples: the effect of time and temperature
    Marianne Morris
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, UK
    J Immunol Methods 266:111-6. 2002
    ....
  69. pmc Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey
    O Noel Gill
    HIV and STI Department, and CJD Section, National Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK
    BMJ 347:f5675. 2013
    ....
  70. ncbi request reprint Model selection methodology for inter-laboratory standardisation of antibody titres
    George Kafatos
    Statistics Unit, Communicable Disease Surveillance Centre, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 23:5022-7. 2005
    ..If the standardisation equations explained sufficient variability, these were used to convert each country's main serum bank results to a common unitage, thereby allowing international comparisons to be made...
  71. ncbi request reprint Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40
    Wendy A Knowles
    Enteric, Respiratory and Neurological Virus Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London, United Kingdom
    J Med Virol 71:115-23. 2003
    ..There is no serological evidence that SV40 entered the human population during the past 80 years, and the possibility of cross-reaction with BKV or JCV antibody must be considered...
  72. pmc Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom
    Richard G Pebody
    Health Protection Agency, London, UK
    Emerg Infect Dis 17:990-9. 2011
    ..9% (1/34) when the primary contact was a man (p = 0.010). Of 53 confirmed secondary case-patients, 45 had not received AV prophylaxis. The effectiveness of AV prophylaxis in preventing infection was 92%...
  73. ncbi request reprint Estimating the number of deaths with rotavirus as a cause in England and wales
    Mark Jit
    Modelling and Economics Unit, Immunisation Department, Health Protection Agency, London, UK
    Hum Vaccin 3:23-6. 2007
    ..The two methods gave estimates of 3.8 and 3.2 rotavirus deaths a year respectively...
  74. pmc Linking healthcare associated norovirus outbreaks: a molecular epidemiologic method for investigating transmission
    Ben A Lopman
    Department of Infectious Disease Epidemiology, Imperial College London, London, UK
    BMC Infect Dis 6:108. 2006
    ..Here, we present a combined molecular and statistical method for assessing:1) whether observed clusters provide evidence of local transmission and2) the probability that anecdotally|linked outbreaks truly shared a transmission event...
  75. ncbi request reprint European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus
    Fernando de Ory
    Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
    J Clin Virol 36:111-8. 2006
    ..The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe...
  76. pmc Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England
    Caroline Trotter
    Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, United Kingdom
    Clin Vaccine Immunol 14:863-8. 2007
    ..With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence...
  77. pmc Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England
    Cheryl Cohen
    National Institute for Communicable Diseases, Johannesburg, South Africa
    Emerg Infect Dis 13:12-7. 2007
    ..5%) in 5- to 6-year-olds to 86% (95% CI 74%-93%) in 11- to 12-year-olds (p<0.001 for 1 or 2 doses). Waning immunity may contribute to mumps outbreaks in older vaccinated populations...
  78. ncbi request reprint Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom
    Ray Borrow
    Public Health Laboratory Service Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
    J Infect Dis 186:1353-7. 2002
    ..6; 95% CI, 338.0-2568.1). This is the first demonstration of immunological memory at 4 years of age in children receiving MCC vaccine on the United Kingdom's 2/3/4-month immunization schedule...
  79. ncbi request reprint Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005
    Mehmet Ceyhan
    Department of Pediatric Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey
    Vaccine 25:7233-7. 2007
    ....
  80. pmc Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine
    Paul Balmer
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Laboratory, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom M13 9WZ
    Clin Vaccine Immunol 14:1442-50. 2007
    ..These data provide a baseline for natural immunity to the pneumococcal serotypes analyzed prior to the introduction of pneumococcal conjugate vaccine in the United Kingdom...
  81. ncbi request reprint Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study
    David Goldblatt
    Immunobiology Unit, Institute of Child Health, University College London, UK
    J Infect Dis 192:387-93. 2005
    ..pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S. pneumoniae have been conducted using sophisticated immunological laboratory techniques...
  82. ncbi request reprint Idiopathic thrombocytopenic purpura and the second dose of MMR
    Julia Stowe
    Arch Dis Child 93:182-3. 2008
  83. ncbi request reprint Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers
    David Goldblatt
    Institute of Child Health, University College London, UK
    Pediatr Infect Dis J 25:312-9. 2006
    ..The minimum number of doses of pneumococcal conjugate vaccine required for protection is not known. We studied the immunogenicity of a reduced schedule in infants and toddlers...
  84. doi request reprint Meningococcal C booster not recommended by evidence
    H Lucy Thomas
    BMJ 337:a1139. 2008
  85. doi request reprint European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations
    Anna Giammanco
    Department of Hygiene and Microbiology G D Alessandro, University of Palermo, Palermo, Italy
    Vaccine 26:4486-93. 2008
    ....
  86. ncbi request reprint Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants
    Emma Longworth
    Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Nell Lane, UK
    Vaccine 20:2592-6. 2002
    ..No increase in avidity was observed in the control group. Antibody avidity indices are useful laboratory markers for the priming of immunological memory following vaccination with meningococcal serogroup B OMV vaccines...
  87. pmc Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection
    Moya Burrage
    Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom
    Infect Immun 70:4946-54. 2002
    ....
  88. pmc Social behavior and meningococcal carriage in British teenagers
    Jenny MacLennan
    University of Oxford, Oxford, United Kingdom
    Emerg Infect Dis 12:950-7. 2006
    ..Social behavior, rather than age or sex, can explain the higher frequency of meningococcal carriage among teenagers. A ban on smoking in public places may reduce risk for transmission...
  89. pmc Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom
    Ray Borrow
    PHLS Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
    Infect Immun 71:5549-55. 2003
    ..This study provides the first evidence that the number of doses of MCC-TT used in infant immunization schedules could be decreased...
  90. pmc Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study
    Brent Taylor
    Centre for Community Child Health, Royal Free and University College Medical School, University College London Royal Free Campus, London
    BMJ 324:393-6. 2002
    ..Conclusions: These findings provide no support for an MMR associated "new variant" form of autism with developmental regression and bowel problems, and further evidence against involvement of MMR vaccine in the initiation of autism...
  91. ncbi request reprint Development and evaluation of Varicella zoster virus ELISA for oral fluid suitable for epidemiological studies
    Yamima Talukder
    Centre for Infectious Disease, Department of Virology, Barts and the London School of Medicine and Dentistry, 25 29 Ashfield St, London E1 1BB, UK
    J Virol Methods 128:162-7. 2005
    ..7% overall, varying slightly with age group. The assay was shown to have good potential for use in large-scale epidemiological studies...
  92. pmc Clinical course of hepatitis C virus during the first decade of infection: cohort study
    Helen E Harris
    Public Health Laboratory Service Communicable Disease Surveillance Centre, London NW9 5EQ
    BMJ 324:450-3. 2002
    ..To determine the clinical course of hepatitis C virus in the first decade of infection in a group of patients who acquired their infections on a known date...